Takeda Pharmaceuticals (TAK.US) introduces AC Immune Alzheimer's Abeta vaccine therapy
On May 13, Takeda Pharmaceuticals (TAK.US) announced the introduction of AC Immune's Alzheimer's Abeta vaccine therapy ACI-24.060.
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
Express News | Takeda Pharmaceuticals' fiscal year 2023 revenue increased 5.9% year over year
The Nikkei Average in the backstage started with a depreciation of 69 yen, and Chugai Yakuhin, Mitsui, etc. fell
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 38109.66; -69.80 TOPIX; 2716.38; -7.70 [Backward Closer Overview] The backward Nikkei Average started at 38109.66 yen, 69.80 yen lower than the previous day, and turned downward from the previous draw (38199.10 yen). Nikkei 225 futures during lunchtime fell in the range of 38100 yen to 38220 yen. The dollar and yen depreciated by 20 yen from around 9:00 a.m., and the dollar was at a high level of 1 dollar = 156.40-50 yen. A
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average rebounded slightly, and Advantest boosted by about 33 yen with 1 brand
The number of gains and falls of the Nikkei Average constituent stocks as of closing 14 days ago was 102 stocks with price increases, 123 stocks with price drops, and 0 stocks unchanged. The Nikkei Average rebounded slightly. The front-end transaction was closed at 38199.10 yen (estimated turnover of 990 million shares), 19.64 yen higher (+0.05%) compared to the previous day. The US stock market on the 13th was mixed. The Dow average depreciated by $81.33 (-0.21%) to $39431.51, and the Nasdaq rose 47.37 points (+ 0.29%) to 16388
Express News | Takeda Pharmaceuticals Reaches Alzheimer's Disease Vaccine Development Agreement
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed in late Monday afternoon trading with the NYSE Health Care Index up 0.1% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.2%. The iShares Biotechnology ETF
Sector Update: Health Care
Health care stocks were mixed late Monday afternoon with the NYSE Health Care Index up 0.1% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.2%. The iShares Biotechnology ETF (IBB) added
Alzheimer's vaccine concept stocks rose more than 30% to finalize more than $2 billion agreement with pharmaceutical giants
① Similar to previous infusion therapy, the AC Immune vaccine is designed to produce antibodies against beta-amyloid; ② However, compared to infusion treatment, the vaccine can greatly reduce the number of treatments required; ③ According to the progress of ACI-24.060, there are still several years to go until regulatory approval.
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate
AC Immune SA (IMR.F) said Monday it signed an exclusive option and license agreement with Japan's Takeda Pharmaceutical (TKD.F) for the former's ACI-24.060, a potential Alzheimer's disease drug treatm
AC Immune Rockets 47% on Alzheimer's Therapy Deal With Takeda
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures
US stocks look set to open modestly higher in Monday's trading session as investors await key inflation data coming out during the week. Dow Jones Industrial Average futures were up 0.3%, S&P 500 futu
Alzheimer's Vaccine Licensing Deal Boosts AC Immune
By Eleanor Laise Stock jumps more than 50% on agreement that will help move experimental vaccine into late-stage trials AC Immune S.A. shares (ACIU) jumped more than 50% premarket on Monday after th
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
Takeda Pharmaceutical (TAK) and AC Immune (ACIU) said Monday they have agreed to an exclusive, worldwide option and license agreement for AC Immune's immunotherapies, including its Alzheimer's disease treatment candidate.
AC Immunity Shares Soar on Exclusive License Deal With Takeda
By Dean Seal Shares of AC Immunity surged after the company signed announced an agreement with Takeda Pharmaceutical for an exclusive option to license its active immunotherapy for Alzheimer's diseas
AC Immune And Takeda Sign Exclusive Option and License Agreement For Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease, AC Immune To Receive Upfront Payment Of $100M And Is Eligible ~$2.1B In Milestone
AC Immune And Takeda Sign Exclusive Option and License Agreement For Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease, AC Immune To Receive Upfront Payment Of $100M And Is Eligible
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
May 13, 2024-- Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer's disease.
Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Summary
The following is a summary of the Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript:Financial Performance:Takeda Pharmaceutical reported a 5.9% revenue growth of ov
Fuji HD, Rinnai, etc. (added) Rating
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|------------|------------|------------|---------|<9229>|SunWells |Nomura | “Neutral” | “Buy” |<9434>|SoftBank | Germany | “Hold” | “Buy” |Target Stock Price Change Code
Takeda Pharmaceutical's Attributable Profit Falls 55% in Fiscal 2024
Takeda Pharmaceutical's (TYO:4502) profit attributable to owners of the parent fell 54.6% to 144.1 billion yen in the fiscal year ended March 31, from 317 billion yen a year ago despite an increased r
No Data